Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage

Cell Mol Life Sci. 2005 Aug;62(15):1671-81. doi: 10.1007/s00018-005-5082-7.


The discovery that pyridoxamine (PM) can inhibit glycation reactions and the formation of advanced glycation end products (AGEs) stimulated new interest in this B6 vitamer as a prospective pharmacological agent for treatment of complications of diabetes. The mechanism of action of PM includes: (i) inhibition of AGE formation by blocking oxidative degradation of the Amadori intermediate of the Maillard reaction; (ii) scavenging of toxic carbonyl products of glucose and lipid degradation; and (iii) trapping of reactive oxygen species. The combination of these multiple activities along with PM safety posture it as a promising drug candidate for treatment of diabetic complications as well as other multifactorial chronic conditions in which oxidative reactions and carbonyl compounds confer pathogenicity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Diabetes Complications / drug therapy
  • Diabetes Complications / etiology
  • Glycation End Products, Advanced / biosynthesis*
  • Humans
  • Maillard Reaction
  • Oxidative Stress / drug effects*
  • Pyridoxamine / chemistry
  • Pyridoxamine / pharmacology*
  • Pyridoxamine / therapeutic use
  • Reactive Oxygen Species / metabolism


  • Glycation End Products, Advanced
  • Reactive Oxygen Species
  • Pyridoxamine